AstraZeneca's Truqap Fails to Meet Goals in Late-Stage Breast Cancer Trial

AstraZeneca announced on June 18, 2024, that its breast cancer drug Truqap, when used with the chemotherapy agent paclitaxel, did not meet its primary endpoints in a late-stage trial aimed at enhancing overall survival for patients with inoperable or metastatic triple-negative breast cancer. The CAPItello-290 trial compared the drug combination to the standard treatment of paclitaxel plus a placebo, and the study failed to achieve its goals in the overall patient population and in a subgroup with specific biomarker alterations. Susan Galbraith, AstraZeneca’s executive vice president of oncology R&D, commented, “While we are disappointed with the CAPItello-290 results, they will help deepen our understanding of the PI3K/AKT pathway’s role in breast cancer.”